Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEP-40 + chitosan is a combination product where the primary active ingredient is **HEP-40**, a highly deacetylated (93%), low-molecular weight chitosan (approximately 40,000 Daltons), manufactured using enzymatic hydrolysis of chitosan derived from chitin in the exoskeleton of crustaceans[1][2]. **HEP-40** functions by binding via its positively charged amino groups to negatively charged lipids and fats in the gastrointestinal tract, limiting their absorption and as a result reducing levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol. It is considered **efficacious and safe** for lowering LDL-C in treatment-naive patients with mild-to-moderate hypercholesterolemia, but is less effective than statins[1][2]. Most adverse reactions are mild and related to the gastrointestinal system (such as constipation and diarrhea).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HEP-40 + chitosan.